Best Biotech Stocks

The BioTech Stocks Package is designed for investors and analysts who need predictions of the best stocks to buy for the whole Biotechnology Industry. It includes 20 stocks with bullish and bearish signals and indicates the best biotech stocks to trade:

• Top 10 Biotech stocks for the long position
• Top 10 Biotech stocks for the short position

Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 3 Days (12/15/2017 – 12/18/2017)
I Know First Average: 3.58%

The algorithm correctly predicted 8 out 10 of the suggested trades in the BioTech Stocks Package for this 3 Days forecast. GHDX was the highest-earning trade with a return of 11.00% in 3 Days. Additional high returns came from INSY and TEVA, at 10.95% and 7.05% respectively. The package had an overall average return of 3.58%, providing investors with a 2.14% premium over the S&P 500’s return of 1.44% during the period.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreements with Epic Sciences, Inc. and BiocartisGroup NV. The company was founded in 2000 and is based in Redwood City, California.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.